India Exchange Filings

Cohance Lifesciences Q2 and H1 FY27 Investor Presentation

Cohance Lifesciences Ltd files a revised Q2/H1 FY27 investor presentation, reporting Q2 revenue of ₹4,767 mn and a 7.4% reported EBITDA margin.

  • Revenue fell 14.2% YoY and rose 12.9% QoQ; adjusted EBITDA margin was 9.6% versus 23.2% in Q2FY26.
  • Reported net profit was ₹152 mn; adjusted net profit was ₹75 mn, versus ₹742 mn and ₹712 mn, respectively, a year earlier.
  • Adjusted EBITDA includes ₹68 mn of one-time ESOP, merger and acquisition costs; management expects H2FY27 to be stronger than H1, supported by Small Molecule deliveries, API+ resilience and Sapala growth.
  • The revised presentation corrects and aligns the version filed on 6 November.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.